antinuclear antibody C-reactive protein erythrocyte sedimentation rate etanercept psoriasis Taiwan tumor necrosis factor a b s t r a c t Background: Psoriasis is a chronic inflammatory disease affecting the quality of life of patients. Traditional treatments are limited by adverse side effects. Etanercept is a biological agent used as an alternative treatment for psoriasis.
Introduction
Psoriasis is a chronic inflammatory dermatological disorder that impairs the quality of life of patients both physically and psychologically. Its prevalence is estimated to be 2%, 1 and the total rate of psoriasis in children younger than 18 years old, including about 3.5e16% infantile patients, 2 has been reported to be 0.71%. 3 In
Taiwan, the mean 1-year prevalence rate is about 0.19%. 4 Traditional therapies such as retinoids, methotrexate, and cyclosporine, sometimes combined with phototherapy, have been in use for a long time, but therapeutic limitations, including elevated liver function and lipid profiles in retinoids, hypertension and impaired renal function in cyclosporine, and liver toxicity in methotrexate, still exist. Moreover, some patients do not respond well to these regimens. Biological agents, such as tumor necrosis factor (TNF) antagonists, have been developed as alternative treatments for psoriasis. Currently available TNF antagonists include infliximab, etanercept, and adalimumab. 5 Etanercept, a human fusion protein, binds to the TNF receptor and inhibits the cascade of the inflammatory process. It has been approved as a treatment for moderate-to-severe plaque psoriasis in the United States and the European Union. 5 In Taiwan, etanercept is used as a second-line treatment for patients with chronic, moderate-to-severe plaque or palmoplantar psoriasis. Previous clinical trials have elucidated that etanercept is effective and safe in treating patients with moderate-to-severe psoriasis.
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There are also published open-label, observational studies showing satisfactory Psoriasis Area and Severity Index (PASI) reduction using etanercept in patients with moderate-to-severe psoriasis in clinical practice. 9, 10 Etanercept is reportedly effective in reducing serum inflammatory markers of psoriasis, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). 11, 12 A retrospective study has shown the role of antinuclear antibody (ANA) as a marker for treatment failure in TNF antagonists. 13 Elevated serum TNF-a levels after using etanercept to treat diseases other than psoriasis has previously been reported.
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This is an open-label, observational, retrospective analysis of the efficacy and safety of etanercept in Asian clinical practice to treat recalcitrant psoriasis patients, namely those who were contraindicated to or failed to improve with at least two traditional regimens plus phototherapy. Relationships between treatment response, and elevated ANA titer and higher serum TNF-a level are also discussed.
Materials and methods

Patients
Between August 2009 and March 2012, 22 Taiwanese adult patients (15 men and seven women; mean age 36.6 years, range 21e70 years) with chronic plaque psoriasis (mean duration 14.8 years, range 6e37 years) were enrolled in the study. Their baseline characteristics are listed in Table 1 . All patients received phototherapy, and 21 received more than two systemic agents for at least 3 months. One patient was not suitable for traditional regimens due to uncontrolled hypertension, abnormal liver function, and high lipid profile. The body surface area remained >10% and the PASI scores >10 in all patients despite traditional treatments.
Treatment protocol
The evaluation period was 24 weeks. All patients received subcutaneous injections of etanercept 50 mg twice a week (BIW) during the first 12 weeks, followed by 25 mg BIW in the next 12 weeks. No concomitant systemic treatment or phototherapy was used. Eight (36.4%) patients did not receive topical medications (topical steroid, coal tar, or vitamin D3 analogs), while 14 (63.6%) received concomitant topical medications.
Efficacy assessment
Evaluation of efficacy included PASI score and laboratory data. At baseline and Weeks 12 and 24, PASI scores and results of blood tests, including ESR, CRP, ANA, TNF-a, were collected. The mean improvement and improvement in PASI scores of !25%, !50%, !75%, and !90% (defined as PASI 25, PASI 50, PASI 75, and PASI 90, respectively) were also assessed.
Safety assessment
Prior to etanercept injection, all patients had received QuantiFERON-TB Gold (QFT-G) test and chest X-ray examination. Neither any positive QFT-G test nor any suspicious tuberculosis infection on chest X-ray was found prior to treatment. All patients received a follow-up of chest X-ray 6 months later. During the study period, blood tests including complete blood cell count with differential count and liver function tests were performed every month. One patient with hepatitis B virus (HBV) infection underwent serum viral load examination prior to treatment and at Week 24. Adverse events of etanercept treatment were assessed in all patients during each clinical visit.
Statistical analysis
The ManneWhitney test was used to compare the PASI improvement between patients treated with and without concomitant topical medications and between those with and without concurrent psoriatic arthritis (PsA). All analyzed results were considered statistically significant at p < 0.05. The relationship between the increment of serum TNF-a level and the PASI improvement was evaluated using linear regression analysis.
Results
Efficacy
The mean PASI score and PASI improvement (%) at baseline and Weeks 12 and 24 are listed in Table 2 . All patients completed the 12-week data collection, while 21 of 22 patients completed the 24-week treatment course. One patient withdrew from the study after Week 12 due to poor compliance. No laboratory data were obtained at Week 12 or 24 for this patient. The mean PASI improvement rate at Week 12 was 49.8%. By Week 24, the mean PASI improvement was 59.8% (Table 2) . At Week 12, 19 (86.3%), 12 (54.5%), three (13.6%), and one (4.5%) patient achieved PASI 25, PASI 50, PASI 75, and PASI 90, respectively. At Week 24, 20 (95.2%), 14(66.7%), five (23.8%), and three (14.3%) patients achieved PASI 25, PASI 50, PASI 75, and PASI 90, respectively ( Figure 1 ). As the treatment period extended, more patients achieved PASI responses.
Six (27.3%) patients had concurrent psoriasis and PsA. The PASI improvement in patients with PsA was 50.8% at Week 12 and 70.0% 
Safety
During the 24-week period, 10 (45.4%) patients had upper respiratory infection. One patient (4.5%) complained of chest tightness, while two (9.1%) had elevated liver function more than twice the upper normal limit. The patient with HBV infection had neither abnormal liver function nor increased viral load. There was no death, malignancy, serious infection, demyelinating disorder, or hematologic abnormality.
Laboratory data
Four (18.1%) patients had elevated ESR level (!15 mm/h) at baseline. At Week 12, all four (100.0%) patients had reduced ESR levels, which they maintained until Week 24 ( Table 2) .
Eight (36.4%) patients had elevated CRP level (!5 mg/L) at baseline. By Week 12, all of them (100%) had reduced CRP levels. By Week 24, five of the eight (62.5%) patients maintained the reduction in CRP levels, while three (37.5%) had higher CRP levels than baseline.
Four ( An open-label study in Greece that used the same dosage of etanercept to treat patients with moderate-to-severe psoriasis revealed that 46.3% patients achieved PASI 75 by Week 12. 11 Another case series study in Taiwan showed that, at Week 12, no statistical significance was noted in PASI improvement between two groups treated with 50 and 25 mg BIW separately (40.8% vs. 49.4%, p ¼ 0.41). 10 In this study, 48%, 26%, and 3% of patients achieved PASI 50, PASI 75, and PASI 90, respectively, at Week 12, which were similar to the results of the present study (Table 3 ). Lower response rates in the present study compared to the data of Western countries might be attributed to the genetic difference, patient characteristics (treatment failed with !2 systemic agents plus phototherapy), and small sample size of the study group. Despite these, patients still achieved satisfactory reduction in PASI scores (reduction of 49.8% and 59.8% at Week 12 and Week 24, respectively). There are limited data to elucidate if patients with concurrent PsA will interfere with the treatment effect of biological agents on psoriasis. In the present study, the effect of etanercept on disease Figure 1 Response rates in patients achieving !25% improvement from baseline in PASI 25, PASI 50, PASI 75, and PASI 90 scores at Weeks 12 and 24. PASI ¼ Psoriasis Area and Severity Index. (Table 5 ). This result may be attributed to the fact that patients with poor psoriasis control needed more therapeutic options. One analysis of three clinical trials using etanercept as a monotherapy in treating psoriasis demonstrated its safety. 7 By Week 12, the most common adverse event was upper respiratory infection (9.5%), followed by headache (8.9%) and injection site ecchymosis (6.4%) in the group with etanercept 50 mg BIW. Percentages of serious adverse events and serious infections were estimated to be 1.1% and 0.3%, respectively. In the current study, 10 (45.5%) patients had upper respiratory infection by Week 12, while no headache or injection site injury occurred. No serious adverse event or infection was noted.
In a retrospective analysis of 17 patients with concurrent psoriasis and HBV or hepatitis C, who were treated with anti-TNFa agents, there was no abnormal liver function or increased viral load. 20 The HBV carrier in the present study also showed no sign of viral reaction. Inflammatory markers for psoriasis had previously been surveyed in one study that enrolled 41 patients treated with etanercept 50 mg BIW. ESR, high-sensitivity CRP, and other markers were measured at baseline and Week 12.
12 By Week 12, all inflammatory markers were reduced (p < 0.001 In conclusion, clinical use of etanercept is effective and safe in Asian patients to treat recalcitrant psoriasis. It can reduce serum levels of inflammatory markers, including ESR and CRP, and occasionally induces positive ANA titers with associated treatment failure. Serum TNF-a level may increase after etanercept treatment but does not seem to influence the PASI improvement.
